Literature DB >> 12324563

Assessing the use of activated protein C in the treatment of severe sepsis.

Jay P Siegel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12324563     DOI： 10.1056/NEJMsb021512

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  29 in total

Review 1.  [Activated protein C. Inevitable in sepsis?].

Authors:  M Max
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

2.  An update on activated protein C (xigris) in the management of sepsis.

Authors:  Cesar Alaniz
Journal:  P T       Date:  2010-09

3.  Evaluation of drotrecogin alpha use in a Belgian university hospital.

Authors:  Isabel Spriet; Wouter Meersseman; Alexander Wilmer; Geert Meyfroidt; Minne Casteels; Ludo Willems
Journal:  Pharm World Sci       Date:  2006-11-17

4.  Activated protein C: do more survive?

Authors:  Alasdair F Mackenzie
Journal:  Intensive Care Med       Date:  2005-10-15       Impact factor: 17.440

Review 5.  Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity.

Authors:  Emanuel P Rivers; Lauralyn McIntyre; David C Morro; Kandis K Rivers
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

6.  The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Authors:  Derek C Angus; Pierre-Francois Laterre; Jeff Helterbrand; E Wesley Ely; Daniel E Ball; Rekha Garg; Lisa A Weissfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

7.  Activated protein C: do more survive?

Authors:  Saxon Ridley
Journal:  Intensive Care Med       Date:  2006-03-01       Impact factor: 17.440

8.  Editors' comments on a new trial of activated protein C for persistent septic shock.

Authors:  Jordi Mancebo; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

Review 9.  Advances in sepsis therapy.

Authors:  Thomas Glück; Steven M Opal
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Advances in Sepsis Treatment.

Authors:  Todd W Rice; Gordon R Bernard
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.